Qlaira® Regulatory Post Marketing Surveillance Study in Korea
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Estradiol valerate/dienogest (Primary)
- Indications Menorrhagia; Pregnancy
- Focus Adverse reactions
- Sponsors Bayer
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2015 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
- 14 Dec 2014 Planned number of patients changed from 720 to 750 as reported by ClinicalTrials.gov.